Genome engineering of stem cells for kidney regeneration

用于肾脏再生的干细胞基因组工程

• 批准号: 10618860
• 负责人: Lauren Elizabeth Woodard
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10618860
• 关键词: Acute Renal Failure with Renal Papillary Necrosis; Admission activity; Adult; Affect; Allogenic; Animal Model; Animals; Aristolochic Acids; Autologous Stem Cell Transplantation; Autologous Transplantation; Biological Markers; Birth; Cell Line; Cell Separation; Cell Therapy; Cells; Cessation of life; Chronic Kidney Failure; Clinic; Clinical; Data; Development; Diagnosis; Dialysis procedure; Doxycycline; Embryo; End stage renal failure; Engraftment; Epithelial Cells; Ethics; Exhibits; Fetal Development; Fetus; Firefly Luciferases; Foundations; Gene Modified; Genes; Genetic Diseases; Genetic Engineering; Genome; Genome engineering; Growth Factor; Histology; Home; Homing; Homologous Transplantation; Human; Immune; Injury; Injury to Kidney; Intensive Care Units; Ischemia; Kidney; Kidney Diseases; Kidney Transplantation; Legal patent; Life; Luciferases; Measures; Mesenchyme; Methods; Mitochondria; Modeling; Morbidity - disease rate; Mus; Mutation; Natural regeneration; Nephrology; Nephrons; Optical Tomography; Outcome; Patient Admission; Patients; Persons; Phenotype; Printing; Production; Property; Proximal Kidney Tubules; Publishing; Recurrence; Regenerative engineering; Renal Replacement Therapy; Renal function; Reperfusion Injury; Reperfusion Therapy; Rhabdomyolysis; Severities; Site; Source; Techniques; Technology; Testing; Therapeutic; Time; Toxin; Transfection; United States; Urine; Veterans; adult stem cell; cancer therapy; cell type; cost; donor stem cell; engineered stem cells; fetal; functional improvement; gene therapy; immunogenic; improved; in vivo; induced pluripotent stem cell; injured; injury and repair; interest; kidney cell; kidney repair; military veteran; mortality; mouse model; nephron progenitor; novel therapeutics; optical imaging; paracrine; pre-clinical; programs; regenerative; renal damage; renal ischemia; repaired; stem cell biomarkers; stem cell therapy; stem cells; tomography; transcription factor; transplantation therapy

We propose to develop a regenerative gene and cell therapy treatment for acute kidney injury and/or chronic kidney disease. These studies are based on recent advances in isolation of adult stem cells from the urine. Urine-derived stem cells have several remarkable properties: they are easy to obtain, propagate for many passages, are multipotent, and home to sites of injury. We propose to genome modify urine-derived stem cells and track their homing in three mouse models of kidney injury (ischemia reperfusion, rhabdomyolysis, and aristolochic acid). Cells will be modified with transposons to express luciferase. This will permit tracking in live animals by optical imaging together with new techniques for advanced tomography. Biomarkers for kidney injury will be measured and compared. Histology and marker analysis will determine if stem cells have an effect on the mouse phenotype for each condition. Aim 1 seeks to compare outcomes for mice receiving urine-derived stem cells vs no treatment. In Aim 2, urine-derived stem cells will be reprogrammed into induced nephron progenitor cells and compared to past methods of deriving induced nephron progenitor cells. These cells are unique because they are similar to cells found in the cap mesenchyme and are capable of differentiating into all parts of the nephron. These aims will determine if allogeneic or autologous stem cell transplant therapies based on urine- derived stem cells may have the ability to reverse or delay kidney damage in mouse models of acute kidney injury or chronic kidney disease.

我们建议开发用于急性肾损伤和/或慢性肾损伤的再生基因和细胞疗法。 肾病这些研究是基于从尿液中分离成体干细胞的最新进展。 尿源性干细胞具有几个显著的特性：它们容易获得， 通道，是多能的，并且是损伤部位的家园。我们建议对尿源性干细胞进行基因组修饰 并在三种肾损伤小鼠模型（缺血再灌注、横纹肌溶解和 马兜铃酸）。将用转座子修饰细胞以表达荧光素酶。这将允许实时跟踪 通过光学成像和先进的断层扫描新技术来观察动物。肾损伤的生物标志物 将被测量和比较。组织学和标记物分析将确定干细胞是否对组织有影响。 小鼠表型。目的1旨在比较接受尿源性干细胞的小鼠的结局 细胞vs无处理。在目标2中，尿来源的干细胞将被重编程为诱导的肾单位祖细胞 细胞并与过去的衍生诱导肾单位祖细胞的方法进行比较。这些细胞是独一无二的 因为它们与帽间充质中发现的细胞相似，并且能够分化成 肾单位这些目标将决定基于尿液的同种异体或自体干细胞移植疗法- 衍生的干细胞可能具有逆转或延迟急性肾损伤小鼠模型中的肾损伤的能力 损伤或慢性肾病。